The US Government Accountability Office publishes the results of its study into the prescription drug industry

Prior to the year-end holiday season, the United States Government Accountability Office (“GAO”) released the results of its long-awaited study into the prescription drug industry’s “Profits, Research and Development Spending, and Merger and Acquisition Deals.” [1] The report responds to Congressional inquiries related to increasing consumer spending on prescription drugs. Importantly, the GAO report, whose findings are based on industry players’ financial performance, R&D spending, clinical trials, and published studies from industry experts, contains several observations about the potential

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Baker Botts (Washington)
  • Baker Botts (Brussels)
  • Gibson Dunn (Washington)
  • Gibson Dunn (Washington)

Quotation

Nathan Chubb, Catriona Hatton, Michael J. Perry, Stephen Weissman, The US Government Accountability Office publishes the results of its study into the prescription drug industry, 1 November 2017, e-Competitions November 2017, Art. N° 95042

Visites 31

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues